Zobrazeno 1 - 10
of 108
pro vyhledávání: '"Linda Morrow"'
Autor:
John Stewart, Marcus Hompesch, Jahoon Kang, OakPil Han, Michael E Trautmann, Christopher H Sorli, Ike Ogbaa, Linda Morrow
Publikováno v:
BMJ Open Diabetes Research & Care, Vol 9, Iss 1 (2021)
Introduction To evaluate the effects of efpeglenatide, a long-acting glucagon-like peptide-1 receptor agonist (GLP-1 RA), on gastric emptying, glucose metabolism, and islet beta-cell function versus liraglutide and placebo in people with type 2 diabe
Externí odkaz:
https://doaj.org/article/0f97f81f7a354a72815a206a028b3d29
Autor:
Stanko Skrtic, Björn Tyrberg, Malin Broberg, Hans Ericsson, Volker Schnecke, Magnus Kjaer, Marcus Hompesch, Eva-Marie Andersson, Erik Ryberg, Alexander Aivazidis, Charlotte Wennberg Huldt, Lars Löfgren, Linda Morrow, Joanna Parkinson, Tina Rydén-Bergsten, Elaine Watkins, Maria Sörhede Winzell
Publikováno v:
PLoS ONE, Vol 13, Iss 12, p e0208998 (2018)
AIMS/HYPOTHESIS:GPR44 (DP2, PTGDR2, CRTh2) is the receptor for the pro-inflammatory mediator prostaglandin D2 (PGD2) and it is enriched in human islets. In rodent islets, PGD2 is produced in response to glucose, suggesting that the PGD2-GPR44/DP2 axi
Externí odkaz:
https://doaj.org/article/14eb9641fd434a2fbeda8df2991ce6e8
Autor:
Sue Sha, Damayanthi Devineni, Atalanta Ghosh, David Polidori, Marcus Hompesch, Sabine Arnolds, Linda Morrow, Heike Spitzer, Keith Demarest, Paul Rothenberg
Publikováno v:
PLoS ONE, Vol 9, Iss 8, p e105638 (2014)
This randomized, double-blind, placebo-controlled, single and multiple ascending-dose study evaluated the pharmacodynamic effects and safety/tolerability of canagliflozin, a sodium glucose co-transporter 2 inhibitor, in patients with type 2 diabetes.
Externí odkaz:
https://doaj.org/article/702046dc63b143b9a12cc8bdb0fc7c0f
Autor:
Derek J Nunez, Mark A Bush, David A Collins, Susan L McMullen, Dawn Gillmor, Glen Apseloff, George Atiee, Leonor Corsino, Linda Morrow, Paul L Feldman
Publikováno v:
PLoS ONE, Vol 9, Iss 4, p e92494 (2014)
GPR119 receptor agonists improve glucose metabolism and alter gut hormone profiles in animal models and healthy subjects. We therefore investigated the pharmacology of GSK1292263 (GSK263), a selective GPR119 agonist, in two randomized, placebo-contro
Externí odkaz:
https://doaj.org/article/74b4a7893b1c4e2f9bf115e1a0fa43ef
Autor:
Rohit, Loomba, Eric J, Lawitz, Juan Pablo, Frias, Grisell, Ortiz-Lasanta, Lars, Johansson, Bridgette Boggess, Franey, Linda, Morrow, Moti, Rosenstock, Cynthia L, Hartsfield, Chao-Yin, Chen, Leo, Tseng, R Will, Charlton, Hank, Mansbach, Maya, Margalit
Publikováno v:
The Lancet Gastroenterology & Hepatology. 8:120-132
Management strategies for non-alcoholic steatohepatitis (NASH) are based predominantly on lifestyle modification, with no approved disease-modifying drugs yet available. We aimed to evaluate the safety, pharmacokinetics, and pharmacodynamics of pegoz
Autor:
Linda, Morrow, Beverly, Greenwald
Publikováno v:
Gastroenterology Nursing. 45:113-119
Cancer is the second leading cause of death in the United States with an estimated 1,806,590 new cases and 606,520 deaths in 2020. Cancer is a public health concern due to the numbers of cases, financial costs, and morbidity and mortality rates. An e
Autor:
Frederico G. S. Toledo, William F. Martin, Linda Morrow, Carine Beysen, Daiva Bajorunas, Ying Jiang, Bernard L. Silverman, David McDonnell, Mark N. Namchuk, John W. Newcomer, Christine Graham
Publikováno v:
Neuropsychopharmacology
A combination of olanzapine and samidorphan (OLZ/SAM) received US Food and Drug Administration approval in May 2021 for the treatment of adults with schizophrenia or bipolar I disorder. OLZ/SAM provides the efficacy of olanzapine, while mitigating ol
Autor:
Linda Morrow, Beverly Greenwald
Publikováno v:
Gastroenterology Nursing. 46:76-77
Autor:
Marc K. Hellerstein, Patrick Kelly, Kiran Dole, Lars Johansson, Kelvin W. Li, Eric Q. Wu, Carine Beysen, Terry E O’Reilly, Marcus Hompesch, Linda Morrow, Wei Lu, Patricia Schroeder, Julie Brevard, Maria D. Ribadeneira
Publikováno v:
Diabetes, Obesity & Metabolism
Aims To assess the therapeutic potential of fatty acid synthase (FASN) inhibition with FT‐4101, a potent, selective, orally bioavailable, small‐molecule by (a) evaluating the dose−response of single FT‐4101 doses (3, 6 and 9 mg) on hepatic de
Autor:
Chin Wong, Thomas Gelzleichter, Junichiro Sonoda, Amos Baruch, Linda Morrow, Suresh Dheerendra, Leslie W. Chinn, Richard Boismenu, Eric Wakshull, Maria E. Wilson, Puneet S. Arora, Shan Chen, Anjali Vaze, Johnny Gutierrez, Nicholas Lewin-Koh
Publikováno v:
Proceedings of the National Academy of Sciences of the United States of America
Significance Fibroblast growth factor 21 (FGF21) controls metabolic organ homeostasis and eating behavior via FGF receptor 1/Klothoβ (FGFR1/KLB) complexes. Here we show that a bispecific anti-FGFR1/KLB agonist antibody, BFKB8488A, mimics the actions